INAB
IN8BIO, INC.
Key Financials
Operating Income
$-19440000
↑ 36.1%
Net Income
$-19440000
↑ 36.1%
Total Assets
$32.3M
↑ 54.1%
EPS (Diluted)
$-4.44
↓ 678.9%
Total Liabilities
$4.7M
↓ 26.9%
Operating Cash Flow
$-12712000.00
↑ 47.4%
Shareholders' Equity
$27.6M
↑ 90.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| S-8 | 8/7/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 8-K | 6/1/2026 | View on SEC |
| 424B5 | 6/1/2026 | View on SEC |
| SCHEDULE 13D/A | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| EFFECT | 5/19/2026 | View on SEC |
| S-3/A | 5/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INAB |
| Company Name | IN8BIO, INC. |
| CIK | 1740279 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (646) 600-6438 |